FogPharma

Executive Summary

FogPharma is a clinical-stage biotechnology company pioneering Helicon™ polypeptides, a novel class of drugs that combine the cell-penetrating properties of small molecules with the target specificity of antibodies. These molecules are designed to inhibit intracellular protein-protein interactions, an area historically considered undruggable. The company's lead program, FOG-001, targets β-catenin, a key oncogenic driver in multiple cancers. With $323 million raised to date, FogPharma is advancing its platform toward clinical proof-of-concept.

Upcoming Catalysts (preview)

• H2 2026Phase 1 interim data readout for FOG-001 (β-catenin inhibitor)60% success
• 2026Series D financing or potential partnership deal70% success
• Q4 2026IND acceptance for second Helicon polypeptide candidate80% success